Camostat mesylate against SARS‐CoV‐2 and COVID‐19—Rationale, dosing and safety

P Breining, AL Frølund, JF Højen… - Basic & clinical …, 2021 - Wiley Online Library
The coronavirus responsible for COVID‐19, SARS‐CoV‐2, utilizes a viral membrane spike
protein for host cell entry. For the virus to engage in host membrane fusion, SARS‐CoV‐2 …

Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches

M Gioia, C Ciaccio, P Calligari, G De Simone… - Biochemical …, 2020 - Elsevier
In the Fall of 2019 a sudden and dramatic outbreak of a pulmonary disease (Coronavirus
Disease COVID-19), due to a new Coronavirus strain (ie, SARS-CoV-2), emerged in the …

Therapeutic strategies against COVID-19 and structural characterization of SARS-CoV-2: a review

GU Jeong, H Song, GY Yoon, D Kim… - Frontiers in …, 2020 - frontiersin.org
The novel coronavirus, SARS-CoV-2, or 2019-nCoV, which originated in Wuhan, Hubei
province, China in December 2019, is a grave threat to public health worldwide. A total of …

A review on SARS-CoV-2-induced neuroinflammation, neurodevelopmental complications, and recent updates on the vaccine development

M Karnik, NM Beeraka, CA Uthaiah, SM Nataraj… - Molecular …, 2021 - Springer
Abstract Coronavirus disease 2019 (COVID-19) is a devastating viral infection caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The incidence and …

[HTML][HTML] Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials

RA Al-Horani, S Kar, KF Aliter - International Journal of Molecular …, 2020 - mdpi.com
The ongoing pandemic of coronavirus disease-2019 (COVID-19) is being caused by severe
acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The disease continues to present …

High-throughput virtual screening approach of natural compounds as target inhibitors of plasmepsin-II

F En-Nahli, S Baammi, H Hajji… - Journal of …, 2023 - Taylor & Francis
Plasmepsin II is a key enzyme in the life cycle of the Plasmodium falciparum parasite
responsible for malaria, a disease that is causing deaths on a worldwide scale. Recently …

Challenges and toxicity assessment of inorganic nanomaterials in biomedical applications: Current status and future roadmaps

P Mahamuni-Badiger, MJ Dhanavade - Journal of drug delivery science …, 2023 - Elsevier
Nano-world is expanding rapidly due to the amalgamation of different science disciplines.
Nanomaterials (NMs) have wide applications in the biomedical field due to their unique …

[HTML][HTML] Discovery of novel TMPRSS2 inhibitors for COVID-19 using in silico fragment-based drug design, molecular docking, molecular dynamics, and quantum …

AA Alzain, FA Elbadwi, FO Alsamani - Informatics in Medicine Unlocked, 2022 - Elsevier
The global expansion of COVID-19 and the mutations of severe acute respiratory syndrome
coronavirus necessitate quick development of treatment and vaccination. Because the …

[PDF][PDF] COVID-19: Fisiopatologia e alvos para intervenção terapêutica

JO De Almeida, VRT De Oliveira, JLS Avelar… - Revista virtual de …, 2020 - academia.edu
The pandemic status of COVID-19 was recorded by the World Health Organization (WHO)
on March 11, 2020. Since then, more than 10 million cases have been confirmed worldwide …

Spiking dependence of SARS‐CoV‐2 pathogenicity on TMPRSS2

AZ Abbasi, DA Kiyani, SM Hamid… - Journal of Medical …, 2021 - Wiley Online Library
Epidemiological data shows a discrepancy in COVID‐19 susceptibility and outcomes with
some regions being more heavily affected than others. However, the factors that determine …